Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)
IXHLMELBOURNE, Australia and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IHL-42X, the Company’s oral fixed-dose combination product candidate for the treatment of obstructive sleep apnea (OSA).
Incannex Healthcare Authorizes $20 Million Share Repurchase Program
IXHLMELBOURNE, Australia and NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact conditions, today announced that its Board of Directors has authorized a share repurchase program (the “Repurchase Program”) for up to $20 million of the Company’s outstanding shares of common stock (“Common Stock”).
Incannex Cancels 347M Warrants to Cut Dilution Ahead of Key Sleep Apnea Trial Results
IXHLIncannex Healthcare To Proceed Phase 3 Component Of RePOSA Clinical Trial Following FDA Authorization
IXHLIncannex Healthcare Agrees To Cancel Remaining 172 Mln Series A Warrants Issued Under Prior Financing Arrangement Contingent Upon Incannex Paying Series A Warrant Holders Cancellation Payment Of Up To $12.2M
IXHLIncannex Healthcare Files Prospectus Supplement To Increase Share Offering Under Sales Agreement To $2.51M
IXHLIncannex Healthcare Q3 EPS $(0.20) Up From $(0.38) YoY
IXHLIncannex Healthcare (IXHL) Stock Soars Over 800%: What's Going On?
IXHLThe drug could could offer a pharmacological alternative to CPAP devices.
Incannex Healthcare Completes Patient Dosing In Phase 2 Portion Of Phase 2/3 RePOSA Study Of IHL-42X In Obstructive Sleep Apnea
IXHLIncannex Completes Phase 2 Enrollment for Sleep Apnea Drug Trial Targeting Better Rest
IXHLIncannex Healthcare Reports Q2 EPS Of $(0.33) Flat YoY; Exits Quarter With Cash & Equivalents Worth $2.1M
IXHLIncannex Healthcare Q1 EPS $(0.29) Down From $(0.08)
IXHL